Please use this identifier to cite or link to this item: https://www.um.edu.mt/library/oar/handle/123456789/2025
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBorg, Nigel-
dc.contributor.authorBaldacchino, Shawn-
dc.contributor.authorSaliba, Christian-
dc.contributor.authorFalzon, Sharon-
dc.contributor.authorDeGaetano, James-
dc.contributor.authorScerri, Christian A.-
dc.contributor.authorGrech, Godfrey-
dc.date.accessioned2015-03-26T10:22:14Z-
dc.date.available2015-03-26T10:22:14Z-
dc.date.issued2014-
dc.identifier.citationXjenza. 2014, Vol.2(1), p. 51-59en_GB
dc.identifier.urihttps://www.um.edu.mt/library/oar//handle/123456789/2025-
dc.description.abstractThe most commonly used biomarkers to predict the response of breast cancer patients to therapy are oestrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2). Patients positive for these biomarkers are eligible for specific therapies such as anti-oestrogen therapy in the event of ER and PgR positivity, and trastuzumab, a monoclonal antibody, in the case of HER2 positive patients. Patients who are negative for all these three biomarkers, the so-called triple negatives, however, derive little benefit from such therapies. The PI3K/Akt pathway is activated in triple negative breast cancer cases, providing a possible target for therapy. The activation of Akt was investigated in Maltese triple negative breast cancer cases using an antibody detecting Akt phosphorylated at serine 473 (anti-Akt pS473). The study showed that 26\% of triple negative breast cancer patients had an elevated level of Akt (pS473). Furthermore, FTY720, a pharmacological activator of the phosphatase PP2A, was shown to block Akt activation at a concentration of 1\textmu M, in HCC1937 cells subjected to insulin-like growth factor 1 (IGF-1). Our data defined a subset of triple negative breast cancer patients based on high activity of AKT (pS473). This subset would be eligible for treatment using therapies which target the PI3K/Akt pathway, such as kinase inhibitors or phosphatase activators. In support of this, the BRCA1 mutant cells (HCC1937) were sensitive to the PP2a activator, FTY720. This suggests that FTY720 is a potential drug for use in adjuvant therapy in breast cancer cases having a high Akt (pS473).en_GB
dc.language.isoenen_GB
dc.publisherMalta Chamber of Scientistsen_GB
dc.rightsinfo:eu-repo/semantics/openAccessen_GB
dc.subjectBiomarkeren_GB
dc.subjectBreast Cancer -- Malta -- Case studiesen_GB
dc.titlePhospho-Akt expression is high in a subset of triple negative breast cancer patientsen_GB
dc.typearticleen_GB
dc.rights.holderThe copyright of this work belongs to the author(s)/publisher. The rights of this work are as defined by the appropriate Copyright Legislation or as modified by any successive legislation. Users may access this work and can make use of the information contained in accordance with the Copyright Legislation provided that the author must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the prior permission of the copyright holder.en_GB
dc.description.reviewedpeer-revieweden_GB
dc.identifier.doi10.7423/XJENZA.2014.1.08-
Appears in Collections:Scholarly Works - FacM&SPat
Xjenza, 2014, Volume 2, Issue 1
Xjenza, 2014, Volume 2, Issue 1

Files in This Item:
File Description SizeFormat 
Phospho-Akt expression is high in a subset of Triple Negative Breast Cancer Patients.pdf4.74 MBAdobe PDFView/Open


Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.